» Articles » PMID: 20472828

B7-H1/CD80 Interaction is Required for the Induction and Maintenance of Peripheral T-cell Tolerance

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2010 May 18
PMID 20472828
Citations 183
Authors
Affiliations
Soon will be listed here.
Abstract

T-cell tolerance is the central program that prevents harmful immune responses against self-antigens, in which inhibitory PD-1 signal given by B7-H1 interaction plays an important role. Recent studies demonstrated that B7-H1 binds CD80 besides PD-1, and B7-H1/CD80 interaction also delivers inhibitory signals in T cells. However, a role of B7-H1/CD80 signals in regulation of T-cell tolerance has yet to be explored. We report here that attenuation of B7-H1/CD80 signals by treatment with anti-B7-H1 monoclonal antibody, which specifically blocks B7-H1/CD80 but not B7-H1/PD-1, enhanced T-cell expansion and prevented T-cell anergy induction. In addition, B7-H1/CD80 blockade restored Ag responsiveness in the previously anergized T cells. Experiments using B7-H1 or CD80-deficient T cells indicated that an inhibitory signal through CD80, but not B7-H1, on T cells is responsible in part for these effects. Consistently, CD80 expression was detected on anergic T cells and further up-regulated when they were re-exposed to the antigen (Ag). Finally, blockade of B7-H1/CD80 interaction prevented oral tolerance induction and restored T-cell responsiveness to Ag previously tolerized by oral administration. Taken together, our findings demonstrate that the B7-H1/CD80 pathway is a crucial regulator in the induction and maintenance of T-cell tolerance.

Citing Articles

PD-L1-CD80 interactions are required for intracellular signaling necessary for dendritic cell migration.

Kantheti U, Forward T, Lucas E, Schafer J, Tamburini P, Burchill M Sci Adv. 2025; 11(5):eadt3044.

PMID: 39879305 PMC: 11777207. DOI: 10.1126/sciadv.adt3044.


PD-1 prelimits both the cytotoxic and exhaustion potential in thymic CD8+ T cells and impacts the maintenance of peripheral tumor immunity.

Mao Z, Hirdler J, Gicobi J, Maynes M, Hsu M, Dellacecca E bioRxiv. 2025; .

PMID: 39868106 PMC: 11761021. DOI: 10.1101/2025.01.18.631253.


Targeting HER2 in Gastroesophageal Cancer: A New Appetite for an Old Plight.

Cammarota A, Woodford R, Smyth E Drugs. 2025; 85(3):361-383.

PMID: 39843758 DOI: 10.1007/s40265-024-02132-2.


CAR-T cell therapy in Multiple Myeloma: current status and future challenges.

Swan D, Madduri D, Hocking J Blood Cancer J. 2024; 14(1):206.

PMID: 39592597 PMC: 11599389. DOI: 10.1038/s41408-024-01191-8.


Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality?.

Brugiapaglia S, Spagnolo F, Intonti S, Novelli F, Curcio C Cells. 2024; 13(18.

PMID: 39329742 PMC: 11430323. DOI: 10.3390/cells13181558.


References
1.
Zhang Y, Chung Y, Bishop C, Daugherty B, Chute H, Holst P . Regulation of T cell activation and tolerance by PDL2. Proc Natl Acad Sci U S A. 2006; 103(31):11695-700. PMC: 1544232. DOI: 10.1073/pnas.0601347103. View

2.
Brown J, Dorfman D, Ma F, Sullivan E, Munoz O, Wood C . Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003; 170(3):1257-66. DOI: 10.4049/jimmunol.170.3.1257. View

3.
Keir M, Liang S, Guleria I, Latchman Y, Qipo A, Albacker L . Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006; 203(4):883-95. PMC: 2118286. DOI: 10.1084/jem.20051776. View

4.
Kong E, Prokunina-Olsson L, Wong W, Lau C, Chan T, Alarcon-Riquelme M . A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum. 2005; 52(4):1058-62. DOI: 10.1002/art.20966. View

5.
Huang C, Workman C, Flies D, Pan X, Marson A, Zhou G . Role of LAG-3 in regulatory T cells. Immunity. 2004; 21(4):503-13. DOI: 10.1016/j.immuni.2004.08.010. View